EGFR and neoplasm: This lack of efficacy may be attributed to factors such as low PD-L1 expression, low tumor mutational burden (TMB), and the upregulation of an immunosuppressive tumor microenvironment (TME), which collectively put EGFR-mutant patients at a disadvantage when receiving ICI treatment (32).